This has been one of the best years to be an active participant in the OTC markets. And the last 3 months have been getting better and better. We think the final run into year-end might be the best of all. Our goal is to help you find that “GI Joe with the Kung Fu Grip” for Christmas this year. And we see ENTB as an incredible opportunity with the potential to get the job done.
The company is starting to get traction in its R&D efforts on the IP front. And it’s working with a tiny float, That’s particularly important in this case given that the stock is starting to see a rapid increase in price per share and average daily trading volume. That spells major squeeze possibilities from present levels.
Entest Biomedical, Inc. (OTCMKTS: ENTB) is a company that focuses on the development and commercialization of immunotherapeutic therapies for the veterinary market in the United States. Between 15 million and 20 million dogs are currently kept as pets in the United States. That’s a huge potential market.
And dogs are living longer and longer, which makes us all happy. But living longer means greater likelihood of developing cancer. About 50% of dogs over ten years old develop a cancer-related condition at some point. In the United States, about 6 million dogs are diagnosed with cancer each year. Again, a huge market. Nobody is dominating this space.
Similarly, the cancer incidence rate for cats is estimated to be about 70 to 80 per 10,000 cats. Cancer is less common in cats than in dogs, but can be quite aggressive. Among cats, common cancers include lymphomas and tumors of the subcutaneous tissues, especially the complex feline fibro-sarcoma. ENTB offers ImenVax family of canine cancer vaccines, such as ImenVax I, a therapeutic for canine cancer, which is involved in isolating tumor cells from the patient and placing the cells into a cell implant device; ImenVax II that utilizes cell lines for sustained release of immunologically relevant cytokines for anti-tumor immune responses; and ImenVax III, a canine cancer vaccine to treat existing tumors through stimulation of immune responses. The company also provides ENT-576 therapy for the treatment of chronic obstructive pulmonary disease; and acquires and operates veterinary hospitals.
In a recent press release, the company revealed that its wholly owned subsidiary, Zander Therapeutics, has announced the filing of a patent application covering composition of matter and methods of use related to molecules identified in their small molecule program that activate and inhibit NR2F6 (‘Small Molecule Modulators of NR2F6 Activity for Animals’).
That will push them further toward the marketplace. NR2F6 is a molecular switch known as an ‘orphan nuclear receptor’, which controls genes associated with the immune response as well as genes associated with the ability of cancer stem cells to propagate.
Zander Therapeutics, Inc. has been granted an exclusive worldwide license by Regen BioPharma, Inc. to develop and commercialize veterinary applications of NR2F6.
Pre-clinical research conducted by Regen BioPharma Inc. (RGBP) and (RGBPP) indicates that by inhibiting NR2F6, cancer stem cells can be converted into normal cells, thus potentially curing the patient of cancer. If that is confirmed by further research, then everyone associated with this technology is going to be rolling in well-earned mountains of cash.
Additionally, activators of NR2F6 have the potential to provide relief from autoimmune diseases such as arthritis. “This is Zander’s first big step towards creating small molecule therapies that can target the NR2F6 molecule, either inhibiting it to treat cancer or activating it to treat arthritis. Both cancer and arthritis have a huge impact on our pets. There are many milestones to achieve before these therapies are able to treat our pets but, this is a critical first step,” said David Koos, Ph.D., CEO of Zander Therapeutics, Inc.
ENTB shares recent found key support and went through a stage of accumulation. However, the stock has started to rip higher in recent weeks, climbing over 300% in the past several months. In that time, we are seeing the single most important attribute of any bottoming rally: increasing average volume as shares increase in price.
If you think about it, if the price per share doubles (or quadruples in this case) and the volume per day stays the same, that means twice as much money is chasing because the same number of shares or being bought up but at twice the price. Well, ENTB has advanced much further than that, and volume here is up 55% on the move. That shows us that a new and growing market is forming around this stock.
It’s being taken seriously by serious investors. And yet the float is just under 17 million shares. In other words, something has to give! At this rate, an explosive squeeze is building.
All the pieces are coming together right now: advances in IP status for the company’s R&D investment, a growing market with no blue chip players, a share mechanics that suggest the potential for a serious rally ahead.
ENTB (Entest Biomedical, Inc. (ENTB)) a company that Entest Biomedical focuses on the development and commercialization of immunotherapeutic therapies for the veterinary market in the United States.
ENTB offers ImenVax family of canine cancer vaccines, such as ImenVax I, a therapeutic for canine cancer, which is involved in isolating tumor cells from the patient and placing the cells into a cell implant device; ImenVax II that utilizes cell lines for sustained release of immunologically relevant cytokines for anti-tumor immune responses; and ImenVax III, a canine cancer vaccine to treat existing tumors through stimulation of immune responses.
ENTB also provides ENT-576 therapy for the treatment of chronic obstructive pulmonary disease; and acquires and operates veterinary hospitals. Entest Biomedical was founded in 2008 and is based in La Mesa, California.
What You Need To Know:
- ENTB is getting R&D traction in a huge and undeveloped niche of canine and feline cancer
- ENTB has a small trading float of just 16.87M, which suggests the stock could launch higher on any additional influx of interest.
- ENTB is showing a clear surge in interest, with volume over the last couple weeks tracking 55% above its recent average levels.
- ENTB is coming off an RSI trough under 40, pointing to a massively oversold stock now heading back the other way.
- ENTB just recorded a MACD Bullish explosion, suggesting a technical confirmation of a new upward trend.
Some other notable biotechnology stocks to keep an eyes include Opko Health Inc (OPK), MannKind Corporation (MNKD), Novavax Inc (NVAX), Amicus Therapeutics Inc (FOLD) and Gilead Sciences (GILD)
DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of journaltranscript.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: